Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Ultracet Combo Product Labeling Cites Faster Pain Action Than Ultram

Executive Summary

Johnson & Johnson's Ultracet delivers a faster onset of action than Ultram (tramadol) alone, labeling for the combination tramadol/acetaminophen drug notes.
Advertisement

Related Content

Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva
Ultram Pain Indication Cannot Be Divided, J&J Says In Response To Teva
J&J Ultram Titration Relabeling Should Not Block Generics, Apotex Argues
J&J Ultram Titration Relabeling Should Not Block Generics, Apotex Argues
Opioid Analgesic Chronic Pain Studies Pose Challenge For FDA
Opioid Analgesic Chronic Pain Studies Pose Challenge For FDA
J&J Ultracet Could Clear FDA In May; Ultram Exclusivity Runs To 2003
J&J Procrit Will Rely On New Indications, DTC To Compete With Amgen NESP
J&J Procrit Will Rely On New Indications, DTC To Compete With Amgen NESP
Advertisement
UsernamePublicRestriction

Register

PS038404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel